The data is out and now available for all potential partners to review. If the drug is a winner which it looks like it is you would hope that a number of partners will show interest and something would happen pretty quickly. After all, if its a winner partners wont want to risk missing out and being beaten to the punch by someone else.
Therefore, the clock starts ticking. I would think that if no news within 2 months, allowing tome for partners to review data and results in detail and get a feel for future requirement from FDA - (i.e need for other small trials post approval) then we should be concerned.
Lets hope that we get a nice easter present
Add to My Watchlist
What is My Watchlist?